CBD and Cannabis Working Group for the Food Industry: Making Sense of the Confusing Regulatory State of Affairs

Jul 14, 2020 1:30pm – 5:00pm

Rend Al-Mondhiry
Amin Talati Wasserman LLP (Washington, DC)

Justin J. Prochnow
Greenberg Traurig

Benjamin Witte
Founder and CEO
Recess (New York, NY)

  • What are the differences between seed which is safe, CBD oils and variants of CBD generally not recognized as safe?
    • CBD as permissible in certain circumstances while THC is not
  • What is FDA’s current stance on the uses of CBD in food products?
  • What does state-level regulation look like?
  • In the absence of FDA’s regulation and resultant state activity, what is a suggested strategy for food companies to employ at this time?
  • What can companies who are currently launching products containing CBD expect to see from FDA?
    • Marketing and labeling: Addressing the effect of making claims that can’t be substantiated
  • What are the anticipated claims involving CBD products?
  • Should food companies which are not currently using CBD products anticipate litigation risks if CBD products accidentally enter their supply chain through cross-contamination?